X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (26095) 26095
Book Review (4804) 4804
Publication (1196) 1196
Newsletter (331) 331
Magazine Article (122) 122
Book Chapter (71) 71
Conference Proceeding (56) 56
Book / eBook (33) 33
Newspaper Article (32) 32
Trade Publication Article (12) 12
Dissertation (10) 10
Transcript (8) 8
Paper (5) 5
Reference (4) 4
Archival Material (1) 1
Data Set (1) 1
Presentation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (23323) 23323
humans (19516) 19516
male (14380) 14380
hypertension - drug therapy (11244) 11244
antihypertensive agents - therapeutic use (11234) 11234
female (11148) 11148
antihypertensive agents - administration & dosage (10082) 10082
hypertension (8702) 8702
middle aged (8580) 8580
blood pressure - drug effects (7438) 7438
aged (6691) 6691
animals (6606) 6606
adult (6220) 6220
antihypertensive agents - pharmacology (5948) 5948
pharmacology & pharmacy (4595) 4595
rats (4445) 4445
hypertension - physiopathology (4125) 4125
treatment outcome (3827) 3827
blood pressure (3821) 3821
antihypertensive agents - adverse effects (3787) 3787
peripheral vascular disease (3262) 3262
drug therapy, combination (3247) 3247
abridged index medicus (2848) 2848
blood-pressure (2840) 2840
antihypertensive drugs (2735) 2735
risk factors (2646) 2646
drug therapy (2465) 2465
dose-response relationship, drug (2296) 2296
time factors (2280) 2280
cardiac & cardiovascular systems (2164) 2164
hypertension - complications (2158) 2158
double-blind method (1940) 1940
medicine, general & internal (1870) 1870
heart rate - drug effects (1853) 1853
aged, 80 and over (1799) 1799
research (1619) 1619
prospective studies (1603) 1603
dosage and administration (1541) 1541
care and treatment (1521) 1521
medicine & public health (1519) 1519
ophthalmology (1500) 1500
angiotensin-converting enzyme inhibitors - therapeutic use (1476) 1476
administration, oral (1380) 1380
therapy (1380) 1380
rats, inbred shr (1354) 1354
follow-up studies (1275) 1275
mortality (1275) 1275
antihypertensive agents (1274) 1274
analysis (1229) 1229
antihypertensive agents - pharmacokinetics (1218) 1218
intraocular pressure - drug effects (1189) 1189
health aspects (1186) 1186
hypertension - diagnosis (1183) 1183
adolescent (1152) 1152
drug combinations (1137) 1137
internal medicine (1111) 1111
rats, sprague-dawley (1111) 1111
drug administration schedule (1095) 1095
management (1088) 1088
angiotensin (1087) 1087
retrospective studies (1075) 1075
risk (1064) 1064
calcium channel blockers - therapeutic use (1063) 1063
glaucoma (1052) 1052
hypertension, pulmonary - drug therapy (1050) 1050
angiotensin-converting enzyme inhibitors - administration & dosage (1039) 1039
blood pressure - physiology (1038) 1038
prevention (1036) 1036
clinical trials as topic (1017) 1017
hemodynamics - drug effects (1010) 1010
rats, wistar (1004) 1004
diuretics (961) 961
disease (957) 957
drugs (938) 938
losartan (926) 926
prevalence (898) 898
hypertension - epidemiology (876) 876
double-blind (870) 870
angiotensin receptor antagonists (865) 865
adrenergic beta-antagonists - therapeutic use (864) 864
cardiology (858) 858
randomized controlled trials as topic (853) 853
disease models, animal (852) 852
patient compliance (815) 815
tetrazoles - administration & dosage (810) 810
hypertension - metabolism (793) 793
renin-angiotensin system - drug effects (791) 791
efficacy (789) 789
diuretics - therapeutic use (787) 787
calcium channel blockers - administration & dosage (779) 779
diabetes (773) 773
tetrazoles - therapeutic use (772) 772
angiotensin-converting enzyme inhibitors - pharmacology (768) 768
pregnancy (757) 757
hypertension - etiology (756) 756
trial (756) 756
amlodipine (734) 734
urology & nephrology (733) 733
pharmacokinetics (723) 723
physiology (722) 722
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (23970) 23970
German (663) 663
Russian (536) 536
French (307) 307
Japanese (307) 307
Spanish (179) 179
Chinese (99) 99
Italian (93) 93
Polish (83) 83
Swedish (69) 69
Danish (58) 58
Norwegian (57) 57
Hungarian (53) 53
Portuguese (39) 39
Czech (30) 30
Romanian (30) 30
Ukrainian (23) 23
Dutch (16) 16
Hebrew (14) 14
Turkish (14) 14
Finnish (12) 12
Slovak (12) 12
Croatian (10) 10
Lithuanian (8) 8
Bulgarian (7) 7
Serbian (7) 7
Korean (2) 2
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet, ISSN 0140-6736, 09/2005, Volume 366, Issue 9489, pp. 895 - 906
The apparent shortfall in prevention of coronary heart disease (CHD) noted in early hypertension trials has been attributed to disadvantages of the diuretics... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | MANAGEMENT | MORBIDITY | DISEASE | GUIDELINES | DOUBLE-BLIND | CALCIUM-ANTAGONISTS | HYPERTENSION | INTERVENTION | Calcium Channel Blockers - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Bendroflumethiazide - administration & dosage | Hypertension - drug therapy | Male | Perindopril - administration & dosage | Sodium Chloride Symporter Inhibitors - administration & dosage | Diuretics | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Blood Pressure - drug effects | Atenolol - administration & dosage | Drug Therapy, Combination | Amlodipine - administration & dosage | Adrenergic beta-Antagonists - administration & dosage | Risk Factors | Amlodipine - adverse effects | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Calcium Channel Blockers - administration & dosage | Atenolol - adverse effects | Hypertension - complications | Aged | Hypertension | Antihypertensive drugs | Evaluation | Dosage and administration | Drug therapy | Prevention | Drug therapy, Combination | Health aspects | Coronary heart disease | Risk factors | Studies | Drugs | Cardiovascular disease | Medical treatment | Myocardial infarction | Heart attacks | Clinical trials | Family medical history | Blood | Randomization | Motivation | Blood pressure | Heart diseases | Antihypertensive agents | Cerebral infarction | Stroke | Fasting | Mortality | Diabetes mellitus | Health risks | Triglycerides | Metabolism | Risk analysis | Atenolol | Fatal | Patients | Coronary artery disease | Cholesterol | Heart rate | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Potassium | Index Medicus | Abridged Index Medicus | Amlodipine/administration & dosage/adverse effects | Bendroflumethiazide/administration & dosage | Cardiovascular Diseases/prevention & control | Perindopril/administration & dosage | MEDICIN OCH HÄLSOVETENSKAP | Atenolol/administration & dosage/adverse effects | Combination | Antihypertensive Agents/administration & dosage/adverse effects | Angiotensin-Converting Enzyme Inhibitors/administration & dosage | MEDICAL AND HEALTH SCIENCES | Coronary Disease/prevention & control | Drug Therapy | Adrenergic beta-Antagonists/administration & dosage/adverse effects | Blood Pressure/drug effects | Hypertension/complications/drug therapy | Calcium Channel Blockers/administration & dosage/adverse effects | Sodium Chloride Symporter Inhibitors/administration & dosage
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2012, Volume 125, Issue 9, pp. 882 - 887.e1
Abstract Objective Combination therapy, specifically with aspirin, cholesterol and blood pressure-lowering drugs, substantially reduces the risk of coronary... 
Internal Medicine | Adherence | Prevention | Cardiovascular disease | PERSISTENCE | ACUTE CORONARY SYNDROMES | CONVERTING ENZYME-INHIBITORS | SECONDARY PREVENTION | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | STATIN THERAPY | ACUTE MYOCARDIAL-INFARCTION | BETA-BLOCKERS | MEDICATION ADHERENCE | ARTERY-DISEASE | Drug Costs | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Medication Adherence - statistics & numerical data | Cardiovascular Agents - administration & dosage | Age Factors | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Antihypertensive Agents - administration & dosage | Secondary Prevention - methods | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Aspirin - administration & dosage | Drug Prescriptions - statistics & numerical data | Self Administration | Time Factors | Anticholesteremic Agents - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Calcium Channel Blockers - administration & dosage | Primary Prevention - methods | Sodium Chloride Symporter Inhibitors - administration & dosage | Myocardial Infarction - prevention & control | Adrenergic beta-Antagonists - administration & dosage | Angiotensin Receptor Antagonists - administration & dosage | Research | Patient compliance | Coronary heart disease | Disease prevention | Prescription drugs | Drug therapy | Meta-analysis | Index Medicus | Abridged Index Medicus | Drugs | Myocardial infarction | Aspirin | Side effects | Enzyme inhibitors | Risk reduction | Age | Statins
Journal Article
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 420 - 428
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 10/2008, Volume 149, Issue 8, pp. 521 - 530
Background: Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension.... 
INHALED ILOPROST | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ORAL SILDENAFIL | EFFICACY | TREPROSTINIL | SAFETY | COMBINATION THERAPY | PROSTACYCLIN | BOSENTAN | Piperazines - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Sulfones - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Dyspepsia - chemically induced | Purines - administration & dosage | Hemodynamics - physiology | Walking - physiology | Sildenafil Citrate | Time Factors | Epoprostenol - adverse effects | Adult | Female | Hypertension, Pulmonary - drug therapy | Purines - adverse effects | Drug Therapy, Combination | Headache - chemically induced | Double-Blind Method | Administration, Oral | Piperazines - adverse effects | Antihypertensive Agents - adverse effects | Adolescent | Quality of Life | Aged | Vasodilator Agents - adverse effects | Hypertension, Pulmonary - etiology | Vasodilator Agents - administration & dosage | Epoprostenol - administration & dosage | Sulfones - administration & dosage | Complications and side effects | Epoprostenol | Dosage and administration | Sildenafil | Drug therapy, Combination | Research | Drug therapy | Pulmonary hypertension | Hypertension | Inhibitor drugs | Patients | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
American Journal of Clinical Nutrition, ISSN 0002-9165, 03/2015, Volume 101, Issue 3, pp. 538 - 548
Background: Recent evidence has indicated that flavanol consumption may have many health benefits in humans, including improved cognitive activities.... 
Lipid peroxidation | Insulin resistance | Cocoa flavanols | Blood pressure | Cognitive function | cognitive function | blood pressure | PROANTHOCYANIDINS | cocoa flavanols | PERFORMANCE | CHOCOLATE | FLAVAN-3-OLS | RICH COCOA | lipid peroxidation | IMPAIRMENT | CARDIOVASCULAR HEALTH | NUTRITION & DIETETICS | MOOD | INSULIN-RESISTANCE | insulin resistance | BRAIN | Beverages - adverse effects | Flavonols - adverse effects | Follow-Up Studies | Humans | Antihypertensive Agents - administration & dosage | Flavonols - therapeutic use | Hypertension - drug therapy | Male | Cognition | Cognitive Dysfunction - prevention & control | Cacao - adverse effects | Aged, 80 and over | Aging | Female | Flavonols - administration & dosage | Hypertension - diet therapy | Double-Blind Method | Dairy Products - adverse effects | Cognitive Dysfunction - metabolism | Insulin Resistance | Nootropic Agents - therapeutic use | Combined Modality Therapy | Antihypertensive Agents - therapeutic use | Cacao - chemistry | Nootropic Agents - adverse effects | Antihypertensive Agents - adverse effects | Hypertension - metabolism | Antioxidants - therapeutic use | Nootropic Agents - administration & dosage | Antioxidants - administration & dosage | Antioxidants - adverse effects | Aged | Lipid Peroxidation | Cohort Studies | Analysis | Beverages | Cocoa | Medical research | Flavonoids | Flavones | Bioflavonoids | Nutritional aspects | Medicine, Experimental | Research | Health aspects | Diet | Vitamin B | Older people | Cognitive ability | Clinical trials | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2032 - 2043
In a 2-by-2 factorial trial, 12,705 persons at intermediate risk were assigned to candesartan plus hydrochlorothiazide or placebo and to rosuvastatin or... 
STROKE | MORTALITY | TRIALS | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | COUNTRIES | THERAPY | MYOCARDIAL-INFARCTION | STRATEGY | PREVENTION | INTERHEART | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Hydrochlorothiazide - administration & dosage | Rosuvastatin Calcium - administration & dosage | Antihypertensive Agents - adverse effects | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Cardiovascular disease | Lipids | Hydrochlorothiazide | Low density lipoprotein | Cholesterol | Disease prevention | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Index Medicus | Abridged Index Medicus | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2009 - 2020
Journal Article